Emcure Pharmaceuticals Reports Robust Q2FY26 Performance with 13% Revenue Growth and 25% Profit After Tax Growth
Ahmedabad, November 13: Emcure Pharmaceuticals (BSE:544210, NSE: EMCURE) today announced its consolidated financial results for the quarter ended September 30th, 2025. The quarter saw strong […]
